Cellaïon
De berekende faillissementskans van Cellaïon over 12 maanden bedraagt 0,3% (zeer laag). De jaarrekening over 2024 toont een negatief eigen vermogen (€-13,85M) en een nettoresultaat van €-7,71M. De cijfers schommelen te sterk van jaar tot jaar voor een betrouwbare trendprojectie. De solvabiliteit is beter dan 5% van 256 sectorgenoten (boekjaar 2024). Het bedrijf is actief sinds 2021 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen.
| Eigen vermogen | €-13,85M |
| Netto resultaat | €-7,71M |
| Werknemers (VTE) | 15,5 |
| Beter dan sector | 5% |
Gemengd profiel: sterk in rentabiliteit, zwakker in gezondheid.
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
De volledige opbouw van de score, de scoregeschiedenis per boekjaar en de indicatieve kredietlimiet ontgrendel je met Plus.
Bekijk plannen →Hoe berekenen we dit?
De trend is een robuuste mediaan van alle paarsgewijze hellingen tussen de boekjaren (Theil-Sen), zodat één afwijkend jaar de lijn niet kan kapen. Voor strikt positieve reeksen rekenen we ook een loggroei-variant (samengestelde jaargroei) en kiezen we de variant die de cijfers het best beschrijft.
De zone rond de projectie is 1,8 × de mediane absolute afwijking van de trend, en verbreedt per jaar vooruit (×1 / ×1,6 / ×2,2), met een minimum van 8% van de laatste waarde. Dit is een indicatieve marge, géén statistisch betrouwbaarheidsinterval.
Een reeks waarvan de afwijkingen meer dan 35% van het niveau bedragen, is te volatiel: dan tonen we bewust géén projectie. Elke projectie veronderstelt ongewijzigd beleid en kent geen niet-publieke informatie (orderboek, contracten, financieringsrondes).
| Kengetal | Dit bedrijf | Sectormediaan | Positie in de sector |
|---|---|---|---|
| Solvabiliteit | -592,9% | 50,6% | |
| Nettoresultaat | €-7,71M | €50k | |
| Eigen vermogen | €-13,85M | €122k | |
| Bruto bedrijfsmarge | €-4,03M | €144k | |
| Personeelskosten | €3,41M | €156k |
| Boekjaar | 2024 |
|---|---|
| Omzet | - |
| EBITDA | €-7,58M |
| Nettoresultaat | €-7,71M |
| Cashflow | €-7,60M |
| Personeelskosten | €3,41M |
| Belastingen op het resultaat | €2k |
| Dividenden | - |
| Totaal activa | €2,34M |
| Eigen vermogen | €-13,85M |
| Schulden | €15,10M |
| waarvan ≤ 1 jaar | €2,50M |
| waarvan > 1 jaar | €12,61M |
| Werkkapitaal | €-376k |
| Werknemers (VTE) | 15,5 |
| 2024 | |
|---|---|
| Current ratio | 0,85 |
| Quick ratio | 0,85 |
| Werkkapitaalratio | -16,1% |
| Solvabiliteit | -592,9% |
| Debt / equity | -1,09 |
| Langetermijnschuldgraad | -0,91 |
| Interest coverage | -105,13 |
| Bruto rentabiliteit | - |
| Netto rentabiliteit | - |
| ROA | -330,1% |
| ROE | 55,7% |
| EBITDA-marge | - |
| Klantenkrediet (DSO) | - |
| Leverancierskrediet (DPO) | 174d |
| Voorraadrotatie | - |
| Voorraaddagen (DSI) | 0d |
| Post | Code | 2024 |
|---|---|---|
| Balans, Activa | ||
| TOTAAL ACTIVA | 20/58 | €2,34M |
| Vaste activa | 21/28 | €214k |
| Oprichtingskosten | 20 | €0 |
| Immateriële vaste activa | 21 | €0 |
| Materiële vaste activa | 22/27 | €0 |
| Financiële vaste activa | 28 | €214k |
| Vlottende activa | 29/58 | €2,12M |
| Voorraden en bestellingen in uitvoering | 3 | €0 |
| Vorderingen op ten hoogste één jaar | 40/41 | €869k |
| Liquide middelen | 54/58 | €1,25M |
| Balans, Passiva | ||
| TOTAAL PASSIVA | 10/49 | €2,34M |
| Eigen vermogen | 10/15 | €-13,85M |
| Inbreng / kapitaal | 10/11 | €7,09M |
| Overgedragen winst (verlies) | 14 | €-20,94M |
| Voorzieningen en uitgestelde belastingen | 16 | €1,08M |
| Schulden | 17/49 | €15,10M |
| Schulden op meer dan één jaar | 17 | €12,61M |
| Schulden op ten hoogste één jaar | 42/48 | €2,50M |
| Handelsschulden op ten hoogste één jaar | 44 | €2,49M |
| Resultatenrekening | ||
| Bruto bedrijfsmarge | 9900 | €-4,03M |
| Bedrijfsresultaat | 9901 | €-7,69M |
| Financiële opbrengsten | 75 | €53k |
| Financiële kosten | 65 | €72k |
| Resultaat vóór belasting | 9903 | €-7,71M |
| Belastingen op het resultaat | 67/77 | €2k |
| Resultaat van het boekjaar | 9904 | €-7,71M |
| Te bestemmen resultaat | 9905 | €-7,71M |
| NACE primair | Gezondheidszorg(86995) |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 02-03-2021 |
| Status | Actief |
| Postcode | 1435 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 25020B0074/00B002 | Wallonië | 6,2 ha | 1 · 17 m² | 7,8 m · 2 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
15-07-2024 Ontbinding en onmiddellijke sluiting van de vereffening
- Ontbinding: 2024-06-03
Technische details
{
"notary": {
"name": "Kim LAGAE",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"auditor": null,
"act_meta": {
"language": "mixed",
"pub_date": "2024-07-15",
"filing_date": null,
"act_kind_objet": "DISSOLUTION DE LA SOCIETE - NOMINATION D\u0027UN LIQUIDATEUR-"
},
"decision": {
"body": "assembl\u00E9e_g\u00E9n\u00E9rale_extraordinaire",
"act_date": "2024-06-03",
"unanimous": null
},
"end_event": {
"reason": "Dissolution par assembl\u00E9e g\u00E9n\u00E9rale",
"art_wvv": [
"2:88"
],
"sub_type": "voluntary_dissolution_with_close",
"closure_effective_date": null,
"dissolution_effective_date": "2024-06-03",
"closure_effective_date_is_approximate": false,
"dissolution_effective_date_is_approximate": false
},
"liquidator": {
"kind": "org",
"org_kbo": "0432.711.951",
"org_name": "Janson",
"person_dob": null,
"person_rrn": null,
"is_judicial": false,
"person_name": null,
"is_remunerated": true,
"person_address": null,
"person_birth_place": null
},
"silent_merger": null,
"court_division": {
"name": "TRIBUNAL BE L\u0027ENTREPRISE DU BRABANT WALLON",
"language": "fr",
"tribunal_type": "entreprise"
},
"books_custodian": null,
"subject_company": {
"kbo": "0764.522.425",
"name_full": "Cella\u00EFon",
"legal_form": "SA"
},
"closure_mandatary": null,
"prior_opening_ref": null,
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Kim Lagae",
"org_rep_person_name": null
},
"co_filed_documents": [
"une exp\u00E9dition conforme de l\u0027acte",
"des procurations",
"le rapport sp\u00E9cial \u00E9tabli par le conseil d\u0027administration conform\u00E9ment \u00E0 l\u0027article 2:71 \u00A72 du Code des soci\u00E9t\u00E9s et des associations",
"le rapport sp\u00E9cial \u00E9tabli par le commissaire conform\u00E9ment \u00E0 l\u0027article 2:71 \u00A72 du Code des soci\u00E9t\u00E9s et des associations"
],
"real_estate_transferred": [],
"shareholder_loan_settled": null,
"financials_at_dissolution": null,
"distribution_to_shareholders": null
}23-06-2023 Kapitaalverhoging van €5.533.714 tot €21.620.314,02
- €16.086.600,02 → €21.620.314,02
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 21620314.02,
"delta_eur": 5533714.0,
"before_eur": 16086600.02,
"share_emission": {
"agio_eur": null,
"share_form": "nominal",
"share_class": "B",
"n_new_shares": 55336,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 100.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 5533714.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Kim Lagae",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-06-23",
"filing_date": "2023-06-21",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2023-06-13",
"unanimous": null,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0764.522.425",
"name_full": "Cella\u00EFon",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"rapport sp\u00E9cial du conseil d\u0027administration",
"rapport du commissaire",
"coordination des statuts"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 256309,
"class_name": "B",
"capital_share_eur": 21620314.02,
"voting_rights_per_share": null
}
]
}02-02-2023 Kapitaalverhoging van €8.000.100 tot €16.086.600,01
- €8.086.500,01 → €16.086.600,01
Technische details
{
"events": [
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 16086600.01,
"delta_eur": 8000100.0,
"before_eur": 8086500.01,
"share_emission": {
"agio_eur": 800010.01,
"share_form": "nominal",
"share_class": "B",
"n_new_shares": 80001,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 0.01
},
"decrease_purpose": null,
"contribution_type": "numeraire",
"paid_up_delta_eur": 8000100.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 80001,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Kim LAGAE",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-02-02",
"filing_date": "2023-01-31",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2022-12-29",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0764.522.425",
"name_full": "Cella\u00EFon",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition conforme de l\u0027acte",
"procurations",
"Rapport sp\u00E9cial du conseil d\u0027administration",
"Rapports du commissaire",
"coordination des statuts"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": null,
"class_name": "Ordinaires",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": null,
"class_name": "Ordinaires sans droit de vote",
"capital_share_eur": null,
"voting_rights_per_share": 0.0
},
{
"n_shares": null,
"class_name": "Classe B",
"capital_share_eur": null,
"voting_rights_per_share": 2.0
}
]
}09-02-2022 Verrichting in kapitaal of aandelen
Technische details
{
"events": [],
"notary": {
"name": "Kim Lagae",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": "2022-01-28",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "notarieel_alleen",
"act_date": "2022-01-17",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0764.522.425",
"name_full": "PROMETHERA BIOSCIENCES Thuofeutico",
"legal_form": "soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Kim Lagae",
"org_rep_person_name": null,
"person_role_at_subject": "notaire instrumentant"
},
"co_filed_documents": [
"exp\u00E9dition de l\u0027acte"
],
"shareholders_after": [],
"share_classes_after": []
}26-01-2022 Kapitaalverhoging
- 2 kapitaalbewegingen in deze akte
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5371749.98,
"delta_eur": 5210249.98,
"before_eur": 61500.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 52102,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "numeraire",
"paid_up_delta_eur": 5210249.98,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"_arith_inconsistent": true,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 8086500.0,
"delta_eur": 2814750.02,
"before_eur": 5371749.98,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 28648,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 100.0
},
"decrease_purpose": null,
"contribution_type": "natura",
"paid_up_delta_eur": 2814750.02,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"_arith_inconsistent": true,
"merger_new_shares_n": 28648,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "actions_ordinaires_sans_droit_de_vote",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": 1.0,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "org",
"name": "Abda Lilly SRL",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "org",
"name": "A Q Invest SRL",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "actions_ordinaires_sans_droit_de_vote",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": 1.0,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Kim Lagae",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2022-01-26",
"filing_date": "2022-01-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2022-01-17",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": "2022-01-17"
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": null,
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": null
},
"subject_company": {
"kbo": "0764.522.425",
"name_full": "Promethera Therapeutics",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal avec annexes",
"procurations",
"rapport sp\u00E9cial du conseil d\u0027administration",
"rapports du commissaire",
"coordination des statuts"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "org",
"name": "Abda Lilly SRL",
"role": null,
"n_shares": null,
"share_class": null
},
{
"kbo": null,
"pct": null,
"kind": "org",
"name": "A Q Invest SRL",
"role": null,
"n_shares": null,
"share_class": null
}
],
"share_classes_after": [
{
"n_shares": 107534,
"class_name": "actions_ordinaires",
"capital_share_eur": 8086500.01,
"voting_rights_per_share": 1.0
},
{
"n_shares": 26669,
"class_name": "actions_ordinaires_sans_droit_de_vote",
"capital_share_eur": 0.01,
"voting_rights_per_share": 0.0
}
]
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | Cellaïon |